Abstract:Background: Psoriatic arthritiS Disease activity Score (PASDAS), GRAppa Composite scorE (GRACE) index, modified Composite Psoriatic Disease activity index (mCPDAI), and Disease activity index for PSoriatic arthritis (DAPSA) are composite indices recently developed to assess disease activity in psoriatic arthritis (PsA).1,2 Guselkumab (GUS) is a monoclonal antibody targeting interleukin-23 that has demonstrated efficacy in a phase 2 PsA trial.3 Objectives: To compare the effect of GUS on disease activity in psoriatic arthritis (PsA) as measured by these composite indices. Methods: In this Phase-2 trial, patients with active PsA (≥3 tender, ≥3 swollen joints, C-reactive protein ≥3 mg/L, ≥3% body surface area) were randomized 2:1 to subcutaneous GUS 100mg (n=100) or placebo (PBO, n=49) at Wk0, Wk4, and every 8 wks through Wk44. At Wk16, patients with Results: Changes in SF-36 PCS score were consistent with disease activity states at Wk24 for each PsA composite index in guselkumab-treated patients. The SMD, ES and SRM indicated that guselkumab elicited a substantial effect in treating the diverse manifestations of PsA compared with placebo, regardless of composite index employed (Figure). PASDAS and GRACE indices appeared to be more sensitive than mCPDAI and DAPSA in detecting changes upon treatment and distinguishing guselkumab treatment effects relative to placebo. Residual disease activities among guselkumab-treated patients who achieved low disease activity at Week24 based on each PsA composite index are summarized in the Table. Conclusion: Regardless of the PsA-specific composite index employed, GUS significantly improved disease activity and achieved clinically meaningful therapeutic targets such as low/minimal disease activity or remission. PASDAS and GRACE indices were more sensitive than mCPDAI and DAPSA in detecting changes in disease activity by guselkumab treatment. References [1] Helliwell PS, et al. JRheumatol2014;41:1212-1217. [2] Scholes MM, et al. AnnRheumDis2016;75:811-818. [3] Deodhar a, et al. Lancet2018;391: 2213–24. Disclosure of interests: Philip Helliwell Grant/research support from: Paid to charity: from abbVie, Janssen and Novartis, Consultant for: Paid to charity: from abbVie, amgen, Pfizer, and UCB and Celgene. Paid to self: from Celgene and Galapagos, atul Deodhar Grant/research support from: abbVie, amgen, Eli Lilly, GSK, Janssen, Novartis, Pfizer, and UCB, Consultant for: abbVie, amgen, BMS, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, alice B Gottlieb Grant/research support from: PI: incyte Corporation, Janssen-Ortho inc., Lilly ICOS LLC, Novartis, UCB, XBiotech, Consultant for: abbVie, Dermira, incyte Corporation, Lilly ICOS LLC, Novartis, Sun Pharmaceutical industries Ltd., avotres (unpaid), XBiotech (unpaid), Speakers bureau: abbVie, Eli Lilly and Company, Janssen Biotech; advisory board: Bristol-Myers Squibb, Celgene Corporation, Janssen Biotech, Janssen-Ortho inc., LEO Pharma, Novartis, UCB, Wolf-Henning Boehncke Consultant for: Pfizer inc, Speakers bureau: Pfizer inc, Xie L Xu Employee of: Employee of Janssen Research & Development, LLC, Stephen Xu Employee of: Employee of Janssen Research & Development, LLC, Yuhua Wang Employee of: Employee of Janssen Research & Development, LLC, Elizabeth C Hsia Employee of: Employee of Janssen Research & Development, LLC, Dafna D Gladman Grant/research support from: abbVie, amgen, Celgene, Lilly, Novartis, Pfizer, and UCB, Consultant for: abbVie, amgen, BMS, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB, Christopher T. Ritchlin Grant/research support from: abbVie, amgen, UCB Pharma, Consultant for: abbVie, amgen, Lilly, Novartis, Pfizer, UCB Pharma

Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis

Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 Trials

Correlation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial

Persistent Patient-Level Effect of Guselkumab at Consecutive 8-Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2-Year, Phase 3, Randomized, Controlled Study

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study

Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials

Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials

Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)

AB0753 COMPARING COMPOSITE MEASURES OF DISEASE ACTIVITY IN PSORIATIC ARTHRITIS: RESULTS FROM A RANDOMIZED PHASE 2 TRIAL WITH GUSELKUMAB

Modulation of IL‐23 Signaling With Guselkumab in Biologic‐Naïve Patients Versus TNF Inhibitor‐Inadequate Responders With Active Psoriatic Arthritis

Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab

Effect of Spesolimab on Achieving Sustained Disease Remission in Patients with Generalized Pustular Psoriasis: Results from the Effisayil 2 Study

Association Between Achievement of Clinical Disease Control and Improvement in Patient-Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT-PsA 1 and 2 Randomized Controlled Trials

51856 Spesolimab Rapidly Improves Quality of Life in Patients with Generalized Pustular Psoriasis, As Per Dermatology Life Quality Index Scores: Data from the Effisayil 2 Trial

Spesolimab Rapidly Improves Quality of Life in Patients with Generalized Pustular Psoriasis, As Per Dermatology Life Quality Index Scores: Data from the Effisayil 2 Trial

A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence

Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors

Association between musculoskeletal sonographic features and response to treatment in patients with psoriatic arthritis

Improvements in patient‐reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial

Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies